Velcade "Impressive" Efficacy Offsets Concerns Over Response As Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
"Impressive" and "better than expected" efficacy results with Millennium’s multiple myeloma agent Velcade were enough to outweigh FDA’s concerns about the use of response rate as a surrogate endpoint, NDA review documents indicate.
You may also be interested in...
Neuropathy Associated With Velcade Appears Reversible, Analysis Shows
Peripheral neuropathy associated with Millennium’s Velcade appears to be reversible in most cases, according to an analysis presented at the American Society of Hematology annual meeting Dec. 9.
Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal
Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.
Velcade Four-Month Review Reflects FDA’s Internal Goal
Approval of Millennium’s Velcade in less than four months reflects FDA’s internal goal to approve the multiple myeloma agent before the full six months allotted for the priority review.